Table 2.
Selected adverse drug reaction newly explained by SPD database
| Drug (targets) | Assay target | AC50 (µM) | Explained ADRs |
|---|---|---|---|
| amiodarone (KCNH2) | HRH1 | 2.4 | akinesia, bradykinesia, decreased activity, disorientation, extrapyramidal disorder, hypokinesia, inappropriate antidiuretic hormone secretion |
| amlodipine (CACNA1C) | ADRB2 | 1.8 | sinus bradycardia |
| DRD2 | 2.9 | parkinsonism | |
| OPRK1 | 1.2 | cardio-respiratory arrest, drug abuse | |
| citalopram (SLC6A4) | DRD1 | 3.9 | akathisia, catatonia, choreoathetosis, dyskinesia, ejaculation disorder, extrapyramidal disorder, libido increased, movement disorder, orgasmic disorders and disturbances, parkinsonism, priapism, psychotic disorder, serotonin syndrome, substance related and addictive disorders, tardive dyskinesia, torticollis, trismus |
| citalopram (SLC6A4) | HRH2 | 0.35 | hyperprolactinemia |
| donepezil (ACHE) | ADRA1A | 4.4 | drooling |
| CHRM2 | 1.1 | extrapyramidal disorder | |
| eletriptan (HTR1B, D, F) | CHRM2 | 4.2 | accommodation disorder |
| fluoxetine (SLC6A4) | OPRK1 | 1.5 | cardio-respiratory arrest, coordination abnormal, delusion, drug abuse |
| lurasidone (DRD2, HTR2A) | ADRA1A | 0.075 | blood prolactin increased, cogwheel rigidity, drooling, muscle rigidity, oculogyric crisis, sexual dysfunction, torticollis |
| CHRM2 | 3.5 | dyskinesia | |
| DRD1 | 0.13 | dyskinesia, sedation, substance related and addictive disorders | |
| pregabalin (CACNA2D1,2) | ADRA1A | 3.7 | autonomic nervous system imbalance, blood prolactin increased, dizziness postural, miosis, orgasmic disorders and disturbances, restlessness, sudden death, torticollis, trismus, urinary incontinence |
| quetiapine (DRD2, HTR2A) | OPRK1 | 1.6 | cardio-respiratory arrest, choreiform movements, coordination abnormal, delusion, drug withdrawal syndrome |
| OPRM1 | 1.8 | drug dependence, respiratory arrest | |
| ranitidine (HRH2) | CHRM2 | 2.6 | dyskinesia |
| sibutramine (SLC6A2,3,4) | HTR2A | 1 | torticollis |
| OPRK1 | 4.8 | delusion | |
| tramadol (OPRM1) | CHRM2 | 1.5 | dyskinesia, parkinsonism |
| trimipramine (SLC6A2,3,4) | CHRM1 | 0.31 | accommodation disorder, mydriasis |
| CHRM2 | 0.16 | accommodation disorder, extrapyramidal disorder, mydriasis, parotid gland enlargement | |
| valbenazine (SLC18A2) | HTR1A | 1.4 | tardive dyskinesia |
| zolpidem (GABRA1) | CHRM1 | 0.21 | accommodation disorder, mydriasis |